Advanced Search

 

Study ID Status Title Patient Level Data
263855/012 Completed Single-blind clinical study of the immunogenicity and reactogenicity of GSK Biologicals dTpa, pa vaccines and a Tdvaccine, given as a booster dose to healthy adults, from the age of 18 years onwards
263855/014 Completed A phase III, double-blind, randomized, single vaccination study of SmithKline Beecham Biologicals’ reduced antigen content diphtheria-tetanus-acellular pertussis and combined diphtheria-tetanus-whole cell Bordetella pertussis vaccines in healthy children.
263855/017 Completed Open, five-year immunogenicity follow-up of subjects who previously received GSK Biologicals dTpa vaccine or GSKBiologicals pa vaccine and Lederles Td vaccine at 10 to 14 years of age in study 263855/004 (EXT: dTpa-004) Study Listed on ClinicalStudyDataRequest.com
263855/019 Completed Open, non-randomized, phase IV study to evaluate immunogenicity and safety of GSK Biologicals’ dTpa vaccine when administered as single dose to healthy adolescents in their 11th to 18th year of life who were not previously vaccinated against pertussis and have anti-PT antibody titers < 20 EL.U/ml  Study Listed on ClinicalStudyDataRequest.com
263855/020 Completed An open, phase III, single center study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ dTpa vaccine administered as a single-dose booster in healthy adults aged ≥ 18 years. Study Listed on ClinicalStudyDataRequest.com
263855/028 Completed Single-blind, randomized, phase IV clinical trial to compare the immunogenicity of GSK Biologicals’ dTpa vaccine (Boostrix™) and Aventis Pasteur MSD’s tetanus toxoid vaccine (Tetavax®), ten days after vaccination of healthy adults 18 years of age and older Study Listed on ClinicalStudyDataRequest.com
263855/029 Completed Observer-blind, randomized, phase II clinical trial to assess the immunogenicity and safety of one dose of three formulations of GSK Biologicals’ dTpa vaccine containing 0.5 mg, 0.3 mg and 0.133 mg of aluminum, respectively in healthy adolescents aged 10 to 18 years Study Listed on ClinicalStudyDataRequest.com
263855/033 Completed Double-blind, randomised phase IIIb, study to compare the immunogenicity and reactogenicity of GSK Biologicals DTPa vaccine (Infanrix™) with GSK Biologicals dTpa (Boostrix™) administered to healthy children 4-6 years of age, having experienced an injection site reaction following the 4th dose of Infanrix™ vaccine Study Listed on ClinicalStudyDataRequest.com
263855/034 Completed Double-blind, randomized, phase III clinical trial to evaluate the immunogenicity and reactogenicity of three consecutive doses of dTpa, or of dTpa-IPV followed by two doses of Td vaccine , and compared to three consecutive doses of Td vaccine administered to healthy adults in a 0,1,6-month schedule Study Listed on ClinicalStudyDataRequest.com
263855/035 Terminated Phase IIIb study to evaluate immunogenicity, antibody persistency and reactogenicity of DTPa - INFANRIX and dTpa - BOOSTRIX vaccines administered to healthy children previously primed with 3 doses of DTPa vaccine compared to placebo (HAVRIX®JUNIOR) Study Listed on ClinicalStudyDataRequest.com
263855/036 Completed Open, phase IIIb, multicentric, safety and reactogenicity study of GSK Biologicals’ reduced antigen content combined diphtheria-tetanus-acellular pertussis vaccine administered as a booster dose to healthy children according to the international recommended prescribing information Study Listed on ClinicalStudyDataRequest.com
27,433 -19 Completed Retrovir® Capsules in the Treatment of HIV-Infected Patients in Renal Failure
270362/002 Completed A phase III open study designed to evaluate the immunogenicity and reactogenicity of a booster dose of Havrix 1440TM in healthy volunteers previously vaccinated with a single dose of SmithKline Beecham Biologicals’ combined Vi polysaccharide typhoid and inactivated hepatitis A vaccine
270362/004 Completed A single-blind, randomized study to evaluate the immunogenicity and reactogenicity of two production lots of GlaxoSmithKline Biologicals’ combined Vi polysaccharide typhoid and inactivated hepatitis A vaccine stored between 2 °C-8 °C for either 0-12 or 24-36 months and administered as a single dose to healthy adult volunteers
270362/006 Completed A phase III, open, randomized, multicentric study to compare the reactogenicity and immunogenicity of GSK Biologicals’ combined Vi polysaccharide typhoid vaccine and inactivated Hepatitis A vaccine, to that elicited by GSK Biologicals’ Hepatitis A vaccine, administered singly or concomitantly with GSK Biologicals’ Vi polysaccharide vaccine Study Listed on ClinicalStudyDataRequest.com
270362/010 Completed A phase IV, open study of re-vaccination with GSK Biologicals’ Vi polysaccharide typhoid vaccine in subjects, who were previously administered a primary vaccination with GSK Biologicals’ combined Vi polysaccharide typhoid and inactivated hepatitis A vaccine or with GSK Biologicals’ Vi polysaccharide typhoid vaccine
275833/030 Completed Protocol SB-275833/030 – Studies 030A and 030B: Two Identical Double-blind, Double-dummy, Multicenter, Comparative Phase III Studies of the Safety and Efficacy of Topical 1% SB-275833, Applied Twice Daily, versus Oral Cephalexin, 500mg in Adults, or 12.5mg/kg (250mg/5ml) in Children, Twice Daily, in the Treatment of Uncomplicated Secondarily Infected Traumatic Lesions (SITL). Study Listed on ClinicalStudyDataRequest.com
275833/032 Completed A Randomized, Double-blind, Double-Dummy, Multicenter, Non-inferiority Phase III Study to Assess the Safety and Efficacy of Topical SB-275833 Ointment, 1%, Applied Twice Daily Study Listed on ClinicalStudyDataRequest.com
29060/001/081 Completed An Open Pharmacokinetic and Pharmacodynamic Study of Paroxetine (20mg, 30mg, or 40mg daily) in the Treatment of Major Depressive Disorder (DSM III)
29060/004 Completed A Double-Blind Extension of Protocol PAR 03
29060/005 Completed A Open-label Long-term Evaluation of Paroxetine in Depressed Outpatients
29060/005_3 Completed An Investigation of the Pharmacokinetics of Paroxetine in Geriatric Patients with Depression
29060/006 Completed A study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo Study Listed on ClinicalStudyDataRequest.com
29060/008 Completed An Open-label, Single-dose, Five-period Crossover Evaluation of the Pharmacokinetic Properties of Paroxetine When Administered by Oral Route
29060/009 Completed A Multicenter, Double-blind, Placebo-controlled Fixed-dose Evaluation of Four Doses of Paroxetine Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.